Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
Caspersen
Sarah
S
Mortensen
Christian
C
Riis
Lene
L
Jess
Tine
T
Bendtsen
Flemming
F
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000069285:Infliximab